Articles tagged "Cytomeglovirus"

2017 American Transplant Congress
Simultaneous Pancreas/Kidney Transplant Recipients Are Predisposed to Symptomatic CMV-Infection and Concomitant Infectious Complications.
T. Schachtner,^1,2,3 M. Zaks,¹ A. Kahl,¹ P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany; ³Berlin Institute of Health BIH, Berlin, Germany
Infections have increased in simultaneous pancreas/kidney transplant recipients (SPKTRs) with CMV-infection being the most important viral infection with adverse impact on patient and allograft outcomes.…
2017 American Transplant Congress
The Combined Effects of Induction Regimens and Antiviral Prophylaxis on the Risk of CMV Infection in Different Serostatus Subgroups After Liver Transplantation.
C. Low,² S. Hosseini-Moghaddam,^1,2 C. Rotstein,² E. Renner,² A. Humar,² D. Kumar,² S. Husain.²
¹Medicine, Western University, London Health Sciences Centre, London, Canada; ²University Health Network, Toronto, Canada
Introduction: Simultaneous effects of anti-CMV prophylaxis and induction regimens on cytomegalovirus (CMV) infection after liver transplantation (LTRs) have not been studied. We determined the magnitude…
2017 American Transplant Congress
High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients.
J. Fose,¹ E. McCreary,¹ M. Jorgenson,¹ M. Lucey,² J. Smith.²
¹Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI; ²Medicine, University of Wisconsin Hospital and Clinics, Madison, WI
Purpose: Evaluate the incidence of cytomegalovirus (CMV) infection in seropositive (R+) solid organ transplant recipients (SOT) receiving high-dose acyclovir (HD-A, 800 mg QID) prophylaxis.Methods: Retrospective…
2017 American Transplant Congress
CMV and BK Virus Infections in Kidney Transplant Recipients Receiving an mTORi-Based Regimen versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis.
B. Tanios,¹ S. Mallat,¹ H. Itani,¹ T. Lotfi,¹ S. Gabardi,² E. Akl,¹ J. Azzi.²
¹Division of Nephrology, American University of Beirut Medical Center, Beirut, Lebanon; ²Renal Division, Harvard Medical School, Boston
The objective of this systematic review is to compare the incidence of CMV and BK virus infections in kidney transplant recipients receiving an mTORi-based as…
2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
M. Pereira,¹ F. Silveira,² G. Papanicolaou,³ A. Langston,⁴ R. Avery,⁵ A. Wijatyk,⁶ J. Wu,⁶ M. Boeckh,⁷ F. Marty,⁸ S. Villano.⁹
¹Columbia University Medical Center, New York, NY; ²University of Pittsburgh Medical Center, Pittsburgh, PA; ³Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Winship Cancer Institute, Atlanta, GA; ⁵Johns Hopkins University, Baltimore, MD; ⁶Shire, Lexington, MA; ⁷Fred Hutchinson Cancer Research Center, Seattle, WA; ⁸Brigham and Women's Hospital, Boston, MA; ⁹Shire (At Time of Study), Wayne, PA
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
2017 American Transplant Congress
Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients.
K. Roach, H. Triemer, M. Hurtik, A. Mehta.
Emory University Hospital, Atlanta, GA
Purpose: The purpose of this study was to evaluate the timeliness of assessment of positive cytomegalovirus (CMV) polymerase chain reaction (PCR) results. This study served…
2017 American Transplant Congress
IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-CMV IgG, Resulting in Inhibition of Antibody (Ab)-Mediated NK Cell Activation in Kidney Transplant Patients (KTX Pts).
B.-H. Shin,¹ S. Ge,¹ M. Chu,¹ J. Choi,¹ L. Winstedt,² C. Kjellman,² S. Louie,¹ A. Vo,¹ A. Peng,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Hansa Medical, Lund, Sweden
Background: Viral infections represent significant morbidity factors for KTx Pts. Ab-dependent cell-mediated cytotoxicity (ADCC) is a major pathway to eliminate virally infected cells and is…
2017 American Transplant Congress
Incidence of Cytomegalovirus Infection Among Liver Transplant Recipients Maintained on a Cyclosporine vs. Tacrolimus-Based Immunosuppression Regimen.
C. Burrelli, M. Bradley, S. Pouch, E. Elkhammas, H. Winters.
The Ohio State University Wexner Medical Center, Columbus, OH
Background: Cytomegalovirus (CMV) is the most common viral pathogen that affects patient outcomes after liver transplant. Potent immunosuppressive agents predispose patients to an increased risk…
2017 American Transplant Congress
Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.
P. Klem,¹ L. Al-Omar,² J. Cooper,² S. Davis,² J. Gralla,² D. Choe,¹ A. Wiseman.²
¹Pharmacy, University of Colorado, Aurora, CO; ²Nephrology, University of Colorado, Aurora
Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…
2017 American Transplant Congress
Improving Donor Screening for Cytomegalovirus (CMV): Is CMV IgG Avidity Better Than CMV IgM?
H. Prince,¹ M. Nowicki.^1,2
¹Donor Screening Laboratory, VRL Eurofins, Los Angeles, CA; ²Mendez National Institute of Transplantation Foundation, Los Angeles, CA
Study purpose: It is standard practice to test organ donors for CMV IgM as a marker of recent CMV infection (defined as primary infection within…